



August 26, 2013

CORRECTING AND REPLACING -- EDAP to Present at Rodman & Renshaw Annual Global Investment Conference, 15th Annual Healthcare Conference Sponsored by H.C. Wainwright & Co.

LYON, France, Aug. 26, 2013 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by EDAP TMS SA (Nasdaq:EDAP), please note that the presentation time should be 10:50 am ET — 11:15 am ET, rather than 10:25 am ET — 10:50 am ET as originally stated. The corrected release follows:

EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Marc Oczachowski, Chief Executive Officer, and Eric Soyer, Chief Financial Officer, are scheduled to present at the Rodman & Renshaw Annual Global Investment Conference that will be held in New York City from September 8 to 10, 2013.

Event: Rodman & Renshaw Annual Global Investment Conference

Presentation Date: Monday, September 09, 2013

Presentation Time: 10:50 am ET — 11:15 am ET

A live Web cast of the presentation will be available on EDAP's Web site at <http://investor.edap-tms.com/events.cfm>. Replay of the Web cast will be available for 30 days after the date of the presentation.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com> and <http://www.hifu-planet.com>.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of uncertainties, including the uncertainties of the FDA PMA review process, our ability to expand our U.S. operations and execute our growth strategy and the market potential for our medical technologies, as well as risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

Investors:

Stephanie Carrington

The Ruth Group

646-536-7017

scarrington@theruthgroup.com

Source: EDAP TMS SA

News Provided by Acquire Media